131I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study

被引：0
|
作者：
Kuan-Yin Ko
Chia-Hung Kao
Cheng-Li Lin
Wen-Sheng Huang
Ruoh-Fang Yen
机构：
[1] National Taiwan University Hospital,Department of Nuclear Medicine
[2] China Medical University,Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine
[3] China Medical University Hospital,Department of Nuclear Medicine and PET Center
[4] China Medical University Hospital,Management Office for Health Data
[5] China Medical University,College of Medicine
[6] Changhua Christian Hospital,Department of Nuclear Medicine
[7] National Taiwan University Hospital,Department of Nuclear Medicine
[8] National Taiwan University College of Medicine,Department of Radiology
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2015年 / 42卷
关键词：
Radioiodine; Thyroid cancer; Salivary gland; Lacrimal gland; Second primary malignancy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1172 / 1178
页数：6
相关论文
共 50 条
  • [1] 131I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study
    Ko, Kuan-Yin
    Kao, Chia-Hung
    Lin, Cheng-Li
    Huang, Wen-Sheng
    Yen, Ruoh-Fang
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (08) : 1172 - 1178
  • [2] Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study
    Lin, Chun-Yi
    Lin, Cheng-Li
    Huang, Wen-Sheng
    Kao, Chia-Hung
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (05) : 685 - 690
  • [3] 131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study
    Lin, Chien-Mu
    Doyle, Pat
    Tsan, Yu-Tse
    Lee, Chang-Hsing
    Wang, Jung-Der
    Chen, Pau-Chung
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (02) : 253 - 259
  • [4] 131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study
    Chien-Mu Lin
    Pat Doyle
    Yu-Tse Tsan
    Chang-Hsing Lee
    Jung-Der Wang
    Pau-Chung Chen
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 253 - 259
  • [5] Second Primary Cancer in Salivary gland cancer: A Nationwide Population-based Study
    Heo, J.
    Oh, Y.
    Noh, O. K.
    Chun, M.
    Kim, C.
    Shin, Y. S.
    RADIOTHERAPY AND ONCOLOGY, 2019, 132 : 73 - 73
  • [6] Thyroid cancer risk after thyroid examination with 131I:: A population-based cohort study in Sweden
    Dickman, PW
    Holm, LE
    Lundell, G
    Boice, JD
    Hall, P
    INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (04) : 580 - 587
  • [7] Use of Radioactive Iodine for Thyroid Cancer and Risk for Second Primary Malignancy: A Nationwide Population-Based Study
    Teng, Chung-Jen
    Hu, Yu-Wen
    Chen, San-Chi
    Yeh, Chiu-Mei
    Chiang, Huey-Ling
    Chen, Tzeng-Ji
    Liu, Chia-Jen
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (02):
  • [8] Second Primary Cancer in Salivary gland cancer in South Korea: A Nationwide Population-based Study
    Heo, J.
    Oh, Y.
    Noh, O. K.
    Chun, M.
    Cho, O.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S365 - S365
  • [9] Association between I-131 treatment for thyroid cancer and risk of developing second primary malignancy_a cohort study from Taiwan
    Lin, C.
    Doyle, P.
    Tsan, Y.
    Chen, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S292 - S292
  • [10] Trends of Second Primary Malignancy in Patients with Thyroid Cancer: A Population-Based Cohort Study in Israel
    Izkhakov, Elena
    Barchana, Micha
    Liphshitz, Irena
    Silverman, Barbara G.
    Stern, Naftali
    Keinan-Boker, Lital
    THYROID, 2017, 27 (06) : 793 - 801
12345